Covered recipient · General Payments record
NELIA ESTHER SANCHEZ-CRESPO
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$2,585.02
22 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,903.00 | 4 |
| Food and Beverage | $682.02 | 18 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ModernaTX, Inc. | $2,228.00 | 5 |
| Exact Sciences Corporation | $88.40 | 4 |
| Novo Nordisk Inc | $70.94 | 3 |
| Lilly USA, LLC | $52.67 | 3 |
| GlaxoSmithKline, LLC. | $42.00 | 2 |
| Hologic Sales and Service, LLC | $23.07 | 1 |
| PFIZER INC. | $22.41 | 1 |
| Bayer Healthcare Pharmaceuticals Inc. | $22.28 | 1 |
| Amgen Inc. | $20.19 | 1 |
| Abbott Laboratories | $15.06 | 1 |
Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NELIA ESTHER SANCHEZ-CRESPO
NPI 1790990851 · CMS profile ID 699626
Allopathic & Osteopathic Physicians / Internal Medicine
HOLLYWOOD, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1790990851?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790990851?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790990851?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- NELIA ESTHER SANCHEZ-CRESPO, NPI 1790990851, CMS profile ID 699626, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1790990851?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
22 matching records · $2,585.02 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–22 of 22.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $24.33 | 12/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032092235 | CMS |
| Lilly USA, LLC | $13.34 | 12/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032092231 | CMS |
| Exact Sciences Corporation | $22.11 | 10/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026564231 | CMS |
| Exact Sciences Corporation | $20.69 | 08/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026564175 | CMS |
| GlaxoSmithKline, LLC. | $21.76 | 08/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1002891871 | CMS |
| ModernaTX, Inc. | $1,281.28 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056981239 | CMS |
| ModernaTX, Inc. | $150.00 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056981243 | CMS |
| ModernaTX, Inc. | $297.72 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056981247 | CMS |
| ModernaTX, Inc. | $325.00 | 07/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056981251 | CMS |
| ModernaTX, Inc. | $174.00 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056981255 | CMS |
| GlaxoSmithKline, LLC. | $20.24 | 05/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1002891829 | CMS |
| Exact Sciences Corporation | $24.03 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026564133 | CMS |
| PFIZER INC. | $22.41 | 05/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050702919 | CMS |
| Amgen Inc. | $20.19 | 05/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020648661 | CMS |
| Lilly USA, LLC | $15.00 | 04/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031968877 | CMS |
| Novo Nordisk Inc | $22.70 | 04/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1002279927 | CMS |
| Novo Nordisk Inc | $23.64 | 04/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1002279941 | CMS |
| Exact Sciences Corporation | $21.57 | 03/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026564099 | CMS |
| Abbott Laboratories | $15.06 | 03/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1018439100 | CMS |
| Novo Nordisk Inc | $24.60 | 02/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1002279955 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $22.28 | 02/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000344483 | CMS |
| Hologic Sales and Service, LLC | $23.07 | 02/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1024880479 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $5,652,523.02 | 227 |
| PY2024 | Principal investigator | $7,882,760.60 | 649 |
| PY2023 | Principal investigator | $10,990,435.50 | 4,306 |
| PY2022 | Principal investigator | $2,420,977.88 | 1,673 |
| PY2021 | Principal investigator | $723,239.31 | 8 |
| PY2020 | Principal investigator | $1,155,430.22 | 12 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
649 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171233 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171237 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,407.20 | 12/31/2024 | Non-covered Recipient Entity Research Centers of America Hollywood | A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V118 Formulation C in Healthy Adults | No dispute reported | 06/30/2026 | 1136437652 |
| Principal investigator 1 | PFIZER INC. | $9,010.17 | 12/31/2024 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1130953257 |
| Principal investigator 1 | PFIZER INC. | $24,931.94 | 12/31/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130964432 |
| Principal investigator 1 | PFIZER INC. | $41,296.58 | 12/27/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130953262 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $445.50 | 12/27/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128702052 |
| Principal investigator 1 | ModernaTX, Inc. | $6,123.60 | 12/23/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153449 |
| Principal investigator 1 | ModernaTX, Inc. | $122,010.30 | 12/23/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147181525 |
| Principal investigator 1 | PFIZER INC. | $3,465.45 | 12/20/2024 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1130953048 |
| Principal investigator 1 | ModernaTX, Inc. | $118,471.30 | 12/19/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147153445 |
| Principal investigator 1 | ModernaTX, Inc. | $297,767.70 | 12/19/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147181517 |
| Principal investigator 1 | PFIZER INC. | $133,004.47 | 12/17/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130953054 |
| Principal investigator 1 | ModernaTX, Inc. | $6,579.04 | 12/13/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147153443 |
| Principal investigator 1 | ModernaTX, Inc. | $5,370.00 | 12/13/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age | No dispute reported | 06/30/2026 | 1147153447 |
| Principal investigator 1 | ABBVIE INC. | $715.50 | 12/12/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1100761291 |
| Principal investigator 1 | ABBVIE INC. | $1,053.50 | 12/12/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1100761293 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 12/11/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148075 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,586.00 | 12/11/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148077 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $750.00 | 12/11/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148079 |
| Principal investigator 1 | PFIZER INC. | $14.10 | 12/10/2024 | Non-covered Recipient Entity Research Centers of America Hollywood | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130919980 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,088.78 | 12/09/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1128702046 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,750.00 | 12/09/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1128702048 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $31.00 | 12/05/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171235 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $354,393.90 | 12/05/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1128702040 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 12/04/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148081 |
| Principal investigator 1 | PFIZER INC. | $43,562.47 | 12/04/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130953251 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $211,755.98 | 12/04/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128702038 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171231 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171411 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171413 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171415 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171417 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171419 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171425 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171427 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $12,450.00 | 11/28/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1128702058 |
| Principal investigator 1 | ModernaTX, Inc. | $82,194.34 | 11/27/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147153435 |
| Principal investigator 1 | ModernaTX, Inc. | $1,504.17 | 11/27/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147153437 |
| Principal investigator 1 | ModernaTX, Inc. | $81,926.10 | 11/27/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153441 |
| Principal investigator 1 | ModernaTX, Inc. | $118,264.50 | 11/27/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147181505 |
| Principal investigator 1 | PFIZER INC. | $1,397.00 | 11/26/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1130974546 |
| Principal investigator 1 | PFIZER INC. | $35,048.16 | 11/23/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130988521 |
| Principal investigator 1 | ModernaTX, Inc. | $972.24 | 11/22/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153439 |
| Principal investigator 1 | PFIZER INC. | $282,469.24 | 11/22/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130975089 |
| Principal investigator 1 | ModernaTX, Inc. | $129.77 | 11/18/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147183919 |
| Principal investigator 1 | ModernaTX, Inc. | $9,050.00 | 11/15/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147153433 |
| Principal investigator 1 | PFIZER INC. | $154,667.41 | 11/05/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130988527 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171229 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171421 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171423 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171429 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171431 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171433 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171435 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171437 |
| Principal investigator 1 | ModernaTX, Inc. | $204.90 | 10/31/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147153457 |
| Principal investigator 1 | ModernaTX, Inc. | $1,105.00 | 10/30/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147153423 |
| Principal investigator 1 | ModernaTX, Inc. | $442.00 | 10/30/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147153425 |
| Principal investigator 1 | PFIZER INC. | $11,293.00 | 10/30/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130998519 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 10/28/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148085 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 10/28/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148097 |
| Principal investigator 1 | ModernaTX, Inc. | $82,323.36 | 10/28/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147153413 |
| Principal investigator 1 | ModernaTX, Inc. | $8,730.20 | 10/28/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147153415 |
| Principal investigator 1 | ModernaTX, Inc. | $39.52 | 10/28/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147153417 |
| Principal investigator 1 | ModernaTX, Inc. | $2,844.20 | 10/28/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147153419 |
| Principal investigator 1 | ModernaTX, Inc. | $39.52 | 10/28/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147153421 |
| Principal investigator 1 | ModernaTX, Inc. | $204.90 | 10/24/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147153451 |
| Principal investigator 1 | PFIZER INC. | $56,173.64 | 10/24/2024 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1130998525 |
| Principal investigator 1 | ModernaTX, Inc. | $102.45 | 10/22/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147153453 |
| Principal investigator 1 | PFIZER INC. | $2,360.00 | 10/21/2024 | Non-covered Recipient Entity Res Cntrs of America HLWD | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130913195 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,998.72 | 10/18/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES | No dispute reported | 06/30/2026 | 1127529737 |
| Principal investigator 1 | Mylan Technologies Inc. | $184,508.75 | 10/16/2024 | Non-covered Recipient Entity Research Centers of America, LLC | MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | No dispute reported | 06/30/2026 | 1134076015 |
| Principal investigator 1 | ModernaTX, Inc. | $8,650.00 | 10/14/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age | No dispute reported | 06/30/2026 | 1147153431 |
| Principal investigator 1 | ModernaTX, Inc. | $47,196.00 | 10/09/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153427 |
| Principal investigator 1 | ModernaTX, Inc. | $24,840.00 | 10/09/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153429 |
| Principal investigator 1 | Mylan Technologies Inc. | $8,000.00 | 10/07/2024 | Non-covered Recipient Entity Research Centers of America, LLC | MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | No dispute reported | 06/30/2026 | 1134076017 |
| Principal investigator 1 | PFIZER INC. | $196,503.31 | 10/05/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130994669 |
| Principal investigator 1 | PFIZER INC. | $1,350.40 | 10/05/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1130998530 |
| Principal investigator 1 | PFIZER INC. | $1,348.75 | 10/05/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1130998626 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 10/02/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148073 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 10/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148083 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 10/02/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148087 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 10/02/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148089 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 10/02/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148091 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 10/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148093 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 10/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148095 |
| Principal investigator 1 | PFIZER INC. | $1,475.00 | 10/02/2024 | Non-covered Recipient Entity Res Cntrs of America HLWD | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130912746 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171179 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171181 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171183 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171193 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171195 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171197 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171199 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171201 |
| Principal investigator 1 | PFIZER INC. | $1,475.00 | 09/30/2024 | Non-covered Recipient Entity Res Cntrs of America HLWD | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130913188 |
| Principal investigator 1 | ModernaTX, Inc. | $35,580.60 | 09/27/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153409 |
| Principal investigator 1 | ModernaTX, Inc. | $9,025.02 | 09/25/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147153405 |
| Principal investigator 1 | PFIZER INC. | $3,620.70 | 09/25/2024 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131012217 |
| Principal investigator 1 | PFIZER INC. | $6,743.75 | 09/25/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131012222 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $7,768.30 | 09/20/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148039 |
| Principal investigator 1 | ModernaTX, Inc. | $399.12 | 09/20/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147153455 |
| Principal investigator 1 | ModernaTX, Inc. | $46,985.40 | 09/18/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153407 |
| Principal investigator 1 | PFIZER INC. | $8,073.50 | 09/14/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1131012135 |
| Principal investigator 1 | Novavax Inc | $2,960.37 | 09/12/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 | No dispute reported | 06/30/2026 | 1123376061 |
| Principal investigator 1 | PFIZER INC. | $1,180.00 | 09/09/2024 | Non-covered Recipient Entity Res Cntrs of America HLWD | A PHASE 1 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE CANDIDATE AGAINST RESPIRATORY SYNCYTIAL VIRUS IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130913191 |
| Principal investigator 1 | ModernaTX, Inc. | $68,700.25 | 09/05/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults | No dispute reported | 06/30/2026 | 1147153411 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,262.00 | 09/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148037 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 09/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148041 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 09/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148043 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 09/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148045 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 09/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148047 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,314.00 | 09/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148049 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $510.00 | 09/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148051 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $902.00 | 09/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148053 |
| Principal investigator 1 | PFIZER INC. | $47,764.78 | 09/04/2024 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131012129 |
| Principal investigator 1 | ModernaTX, Inc. | $94,589.82 | 09/02/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147153403 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171175 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171185 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171187 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171203 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171205 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171207 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171209 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171211 |
| Principal investigator 1 | ModernaTX, Inc. | $77,522.40 | 08/28/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153397 |
| Principal investigator 1 | ModernaTX, Inc. | $9,193.08 | 08/26/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults | No dispute reported | 06/30/2026 | 1147153401 |
| Principal investigator 1 | PFIZER INC. | $69,291.60 | 08/23/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1131033098 |
| Principal investigator 1 | PFIZER INC. | $12,889.60 | 08/22/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1131033105 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 08/22/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1131033341 |
| Principal investigator 1 | ModernaTX, Inc. | $598.68 | 08/20/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147183917 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6.00 | 08/18/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171177 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 08/14/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148067 |
| Principal investigator 1 | ModernaTX, Inc. | $428.10 | 08/12/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age | No dispute reported | 06/30/2026 | 1147153337 |
| Principal investigator 1 | ModernaTX, Inc. | $5,556.75 | 08/08/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age | No dispute reported | 06/30/2026 | 1147153335 |
| Principal investigator 1 | ModernaTX, Inc. | $19,237.50 | 08/08/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age | No dispute reported | 06/30/2026 | 1147153399 |
| Principal investigator 1 | PFIZER INC. | $31,733.82 | 08/06/2024 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131033347 |
| Principal investigator 1 | PFIZER INC. | $20,272.46 | 08/02/2024 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131033530 |
| Principal investigator 1 | ModernaTX, Inc. | $2,012.85 | 08/01/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147153395 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171171 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171173 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171189 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171191 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171213 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171215 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171217 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171219 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171221 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171223 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171225 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171227 |
| Principal investigator 1 | ModernaTX, Inc. | $42,700.50 | 07/29/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153261 |
| Principal investigator 1 | PFIZER INC. | $387,302.40 | 07/26/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1131042556 |
| Principal investigator 1 | ModernaTX, Inc. | $375.00 | 07/24/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147183817 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,102.72 | 07/19/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES | No dispute reported | 06/30/2026 | 1127529741 |
| Principal investigator 1 | Mylan Technologies Inc. | $516,119.50 | 07/19/2024 | Non-covered Recipient Entity Research Centers of America, LLC | MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | No dispute reported | 06/30/2026 | 1134076013 |
| Principal investigator 1 | PFIZER INC. | $8,407.73 | 07/19/2024 | Non-covered Recipient Entity Research Centers of America LLC | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131043617 |
| Principal investigator 1 | ModernaTX, Inc. | $4,080.00 | 07/18/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults | No dispute reported | 06/30/2026 | 1147153267 |
| Principal investigator 1 | PFIZER INC. | $12,289.62 | 07/16/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1131042544 |
| Principal investigator 1 | PFIZER INC. | $438,155.41 | 07/16/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1131042550 |
| Principal investigator 1 | PFIZER INC. | $14.10 | 07/15/2024 | Non-covered Recipient Entity Research Centers of America Hollywood | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130957425 |
| Principal investigator 1 | ModernaTX, Inc. | $12,532.83 | 07/11/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1147153257 |
| Principal investigator 1 | PFIZER INC. | $3,412.80 | 07/09/2024 | Non-covered Recipient Entity Research Centers of America | A PHASE 1 RANDOMIZED OBSERVERBLIND DOSERANGING STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 1130918703 |
| Principal investigator 1 | ModernaTX, Inc. | $3,908.60 | 07/05/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age | No dispute reported | 06/30/2026 | 1147153265 |
| Principal investigator 1 | ModernaTX, Inc. | $201,442.44 | 07/04/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults | No dispute reported | 06/30/2026 | 1147153263 |
| Principal investigator 1 | PFIZER INC. | $115,403.90 | 07/02/2024 | Non-covered Recipient Entity Research Centers of America LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131042527 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 07/01/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148035 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 07/01/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148055 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 07/01/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148057 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 07/01/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148059 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 07/01/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148061 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 07/01/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148063 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,094.00 | 07/01/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148065 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 07/01/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148069 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 07/01/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148071 |
| Principal investigator 1 | ModernaTX, Inc. | $149,883.31 | 07/01/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153259 |
| Principal investigator 1 | PFIZER INC. | $5,266.98 | 06/29/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1131060181 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171119 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171121 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171123 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171125 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171127 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171129 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171131 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171133 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171135 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171137 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171139 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171141 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171143 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171145 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171147 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171149 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171151 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171153 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171155 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171157 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171159 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171161 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171163 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171165 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171167 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171169 |
| Principal investigator 1 | ModernaTX, Inc. | $3,118.98 | 06/27/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age | No dispute reported | 06/30/2026 | 1147153321 |
| Principal investigator 1 | ModernaTX, Inc. | $25,896.24 | 06/27/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147153327 |
| Principal investigator 1 | PFIZER INC. | $7,446.00 | 06/25/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131060186 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,920.00 | 06/21/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128701942 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 06/21/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128701944 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,462.64 | 06/21/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1128701952 |
| Principal investigator 1 | PFIZER INC. | $3,497.00 | 06/19/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131067717 |
| Principal investigator 1 | PFIZER INC. | $18,000.00 | 06/18/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFECT OF PF07293893 ON SKELETAL MUSCLE BIOMARKERS IN HEALTHY ADULT PARTICIPANTS | No dispute reported | 06/30/2026 | 1131060190 |
| Principal investigator 1 | PFIZER INC. | $159.60 | 06/15/2024 | Non-covered Recipient Entity Research Centers of America LLC | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131065934 |
| Principal investigator 1 | ModernaTX, Inc. | $11,342.55 | 06/12/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1147153325 |
| Principal investigator 1 | PFIZER INC. | $31,113.90 | 06/11/2024 | Non-covered Recipient Entity Research Centers of America LLC | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131069844 |
| Principal investigator 1 | ModernaTX, Inc. | $7,800.00 | 06/10/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1147153323 |
| Principal investigator 1 | PFIZER INC. | $127.52 | 06/10/2024 | Non-covered Recipient Entity Research Centers of America | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131017041 |
| Principal investigator 1 | PFIZER INC. | $336.15 | 06/10/2024 | Non-covered Recipient Entity Research Centers of America | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131017047 |
| Principal investigator 1 | ModernaTX, Inc. | $8,239.72 | 06/07/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age | No dispute reported | 06/30/2026 | 1147153333 |
| Principal investigator 1 | ModernaTX, Inc. | $5,058.00 | 06/05/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age | No dispute reported | 06/30/2026 | 1147153331 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $562.55 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147985 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,094.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147987 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,539.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147989 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147997 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147999 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,094.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148001 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,094.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148003 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148005 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148007 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,539.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148009 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148011 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,813.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148013 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,539.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148023 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,539.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148025 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,539.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148027 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,539.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148029 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,539.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148031 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,539.00 | 06/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121148033 |
| Principal investigator 1 | ModernaTX, Inc. | $2,003.82 | 06/03/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153329 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170981 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170983 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171061 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171063 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171065 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171067 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171069 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171071 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171073 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171075 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171077 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171085 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171087 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171089 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171091 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171093 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171095 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171097 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171099 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171101 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171103 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171105 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171107 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171109 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171111 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171113 |
| Principal investigator 1 | Mylan Technologies Inc. | $18,000.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America, LLC | MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | No dispute reported | 06/30/2026 | 1134076005 |
| Principal investigator 1 | Mylan Technologies Inc. | $5,100.00 | 05/31/2024 | Non-covered Recipient Entity Research Centers of America, LLC | MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | No dispute reported | 06/30/2026 | 1134076007 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,493.23 | 05/30/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128701922 |
| Principal investigator 1 | ModernaTX, Inc. | $1,664.28 | 05/29/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147153311 |
| Principal investigator 1 | ModernaTX, Inc. | $5,845.51 | 05/29/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147183807 |
| Principal investigator 1 | ModernaTX, Inc. | $1,607.10 | 05/29/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147183809 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,599.45 | 05/29/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128701938 |
| Principal investigator 1 | PFIZER INC. | $637.60 | 05/28/2024 | Non-covered Recipient Entity Research Centers of America | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131017031 |
| Principal investigator 1 | PFIZER INC. | $672.30 | 05/28/2024 | Non-covered Recipient Entity Research Centers of America | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131017035 |
| Principal investigator 1 | ModernaTX, Inc. | $9,356.94 | 05/27/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age | No dispute reported | 06/30/2026 | 1147153309 |
| Principal investigator 1 | ModernaTX, Inc. | $311,835.30 | 05/27/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153317 |
| Principal investigator 1 | ModernaTX, Inc. | $26,803.40 | 05/27/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults | No dispute reported | 06/30/2026 | 1147153319 |
| Principal investigator 1 | ModernaTX, Inc. | $2,650.00 | 05/24/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153315 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $45,509.95 | 05/24/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128701914 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $39,165.48 | 05/24/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128701916 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $13,148.73 | 05/24/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128701920 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $55,674.84 | 05/24/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128701924 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $45,109.50 | 05/24/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128701926 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $54,561.66 | 05/24/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128701928 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $22,413.04 | 05/24/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128701930 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $32,757.52 | 05/24/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128701932 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $45,670.51 | 05/24/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128701936 |
| Principal investigator 1 | ModernaTX, Inc. | $10,116.00 | 05/23/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153313 |
| Principal investigator 1 | ModernaTX, Inc. | $6,995.00 | 05/09/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147153247 |
| Principal investigator 1 | ModernaTX, Inc. | $6,450.00 | 05/06/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147153305 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 05/01/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147995 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 05/01/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148015 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 05/01/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148017 |
| Principal investigator 1 | ModernaTX, Inc. | $55,665.33 | 05/01/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age | No dispute reported | 06/30/2026 | 1147153307 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170971 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,430.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170973 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170975 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170985 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170987 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170989 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170991 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170993 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,430.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170995 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,430.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170997 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170999 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171001 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171003 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171005 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171039 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171041 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171043 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171045 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171047 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171049 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171051 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171053 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171055 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171057 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171059 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171079 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171081 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171115 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121171117 |
| Principal investigator 1 | ModernaTX, Inc. | $378.52 | 04/26/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147183909 |
| Principal investigator 1 | PFIZER INC. | $381.00 | 04/26/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131077521 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 04/26/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1131088843 |
| Principal investigator 1 | ModernaTX, Inc. | $45.00 | 04/23/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147183907 |
| Principal investigator 1 | ModernaTX, Inc. | $400.00 | 04/19/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147153299 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,362.01 | 04/19/2024 | Non-covered Recipient Entity Research Centers Of America,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128701918 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,226.60 | 04/17/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES | No dispute reported | 06/30/2026 | 1127526980 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $27,649.49 | 04/17/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES | No dispute reported | 06/30/2026 | 1127529739 |
| Principal investigator 1 | PFIZER INC. | $2,500.00 | 04/17/2024 | Non-covered Recipient Entity Research Centers of America LLC | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131088855 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $52,474.60 | 04/17/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older | No dispute reported | 06/30/2026 | 1128701934 |
| Principal investigator 1 | ModernaTX, Inc. | $3,750.00 | 04/15/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147153301 |
| Principal investigator 1 | PFIZER INC. | $4,266.00 | 04/15/2024 | Non-covered Recipient Entity Rseearch Centers of America Hollywood | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1130916859 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $44,594.05 | 04/15/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older | No dispute reported | 06/30/2026 | 1128701940 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,550.09 | 04/12/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND STUDY TO ASSES | No dispute reported | 06/30/2026 | 1127529743 |
| Principal investigator 1 | PFIZER INC. | $4,000.00 | 04/10/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131088849 |
| Principal investigator 1 | PFIZER INC. | $18,648.18 | 04/09/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131077527 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $88.00 | 04/05/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170977 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $66.00 | 04/05/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170979 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $66.00 | 04/05/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171083 |
| Principal investigator 1 | PFIZER INC. | $1,286.70 | 04/05/2024 | Non-covered Recipient Entity Research Centers of America LLC | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131085897 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 04/05/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131085902 |
| Principal investigator 1 | BioNTech SE | $1,920.90 | 04/04/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | BNT162-21 | No dispute reported | 06/30/2026 | 1150661454 |
| Principal investigator 1 | ModernaTX, Inc. | $5,200.00 | 04/04/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age | No dispute reported | 06/30/2026 | 1147153303 |
| Principal investigator 1 | ModernaTX, Inc. | $45.00 | 04/03/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147183905 |
| Principal investigator 1 | PFIZER INC. | $42,689.52 | 04/03/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131086083 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 04/01/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147991 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,976.00 | 04/01/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147993 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,976.00 | 04/01/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148019 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 04/01/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121148021 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170843 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $523.60 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170845 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170847 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170909 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $523.60 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170911 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $523.60 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170913 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $523.60 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170915 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170917 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170919 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170921 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170923 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170925 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170927 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170929 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170931 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170933 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170935 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170937 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170939 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170941 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170943 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170945 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170947 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170949 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170951 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170953 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $523.60 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170955 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170957 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170959 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170961 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170963 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170965 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170967 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170969 |
| Principal investigator 1 | H. Lundbeck A S | $2,367.50 | 03/28/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | STUDY WITH LU AF87908 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1145886466 |
| Principal investigator 1 | ModernaTX, Inc. | $3,800.00 | 03/28/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age | No dispute reported | 06/30/2026 | 1147153279 |
| Principal investigator 1 | ModernaTX, Inc. | $5,824.98 | 03/28/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147153289 |
| Principal investigator 1 | ModernaTX, Inc. | $15,454.80 | 03/28/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153293 |
| Principal investigator 1 | ModernaTX, Inc. | $3,680.00 | 03/28/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults | No dispute reported | 06/30/2026 | 1147153297 |
| Principal investigator 1 | PFIZER INC. | $14,320.84 | 03/28/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131094999 |
| Principal investigator 1 | ModernaTX, Inc. | $5,970.00 | 03/27/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age | No dispute reported | 06/30/2026 | 1147153295 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $45,010.42 | 03/25/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128697598 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $10,065.15 | 03/22/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128697578 |
| Principal investigator 1 | ModernaTX, Inc. | $37,136.27 | 03/21/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147153277 |
| Principal investigator 1 | ModernaTX, Inc. | $46,400.25 | 03/21/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age | No dispute reported | 06/30/2026 | 1147153283 |
| Principal investigator 1 | ModernaTX, Inc. | $4,317.57 | 03/21/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1147153285 |
| Principal investigator 1 | ModernaTX, Inc. | $6,734.88 | 03/21/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147153287 |
| Principal investigator 1 | ModernaTX, Inc. | $296,010.66 | 03/21/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age | No dispute reported | 06/30/2026 | 1147153291 |
| Principal investigator 1 | Novavax Inc | $4,800.00 | 03/21/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 | No dispute reported | 06/30/2026 | 1123376609 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,500.00 | 03/18/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128697582 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $66.00 | 03/13/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170849 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $132.00 | 03/13/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170851 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $176.00 | 03/13/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170853 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $170,727.80 | 03/13/2024 | Non-covered Recipient Entity Research Centers of America Hollywood | An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of Molnupiravir MK-4482 in Participants with Moderate Hepatic Impairment | No dispute reported | 06/30/2026 | 1136418899 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,800.00 | 03/13/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128697584 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $7,250.00 | 03/13/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128697588 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,750.00 | 03/13/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older | No dispute reported | 06/30/2026 | 1128697602 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $9,050.00 | 03/13/2024 | Non-covered Recipient Entity Research Centers Of America,llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128701912 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $400.00 | 03/12/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128697580 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,976.00 | 03/08/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147685 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,976.00 | 03/08/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147827 |
| Principal investigator 1 | ModernaTX, Inc. | $1,250.00 | 03/08/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147183795 |
| Principal investigator 1 | ModernaTX, Inc. | $2,250.00 | 03/08/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147183797 |
| Principal investigator 1 | ModernaTX, Inc. | $569.00 | 03/08/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147183799 |
| Principal investigator 1 | BioNTech SE | $1,920.90 | 03/07/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | BNT162-21 | No dispute reported | 06/30/2026 | 1150661448 |
| Principal investigator 1 | ModernaTX, Inc. | $36,828.12 | 03/06/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age | No dispute reported | 06/30/2026 | 1147153281 |
| Principal investigator 1 | ModernaTX, Inc. | $1,600.00 | 03/06/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147183791 |
| Principal investigator 1 | PFIZER INC. | $5,000.00 | 03/06/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 OPENLABEL SINGLEDOSE PARALLEL GROUP STUDY TO ASSESS PHARMACOKINETICS SAFETY AND TOLERABILITY OF PF07817883 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT | No dispute reported | 06/30/2026 | 1131095017 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,269.00 | 03/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147677 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,269.00 | 03/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147829 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,269.00 | 03/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147831 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,269.00 | 03/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147833 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,269.00 | 03/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147835 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,269.00 | 03/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147837 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,269.00 | 03/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147839 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,269.00 | 03/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147841 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,269.00 | 03/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147843 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,269.00 | 03/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147845 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,269.00 | 03/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147847 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,269.00 | 03/04/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147849 |
| Principal investigator 1 | ModernaTX, Inc. | $375.00 | 03/01/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147183789 |
| Principal investigator 1 | ModernaTX, Inc. | $5,360.00 | 03/01/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147183793 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147927 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147929 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147931 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147933 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147935 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147937 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147939 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147941 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147943 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147945 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147947 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147949 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147951 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147953 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147955 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147957 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147959 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147961 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147963 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147965 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147967 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147969 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147971 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147973 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147975 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147977 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147979 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147981 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147983 |
| Principal investigator 1 | BioNTech SE | $1,920.90 | 02/29/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | BNT162-21 | No dispute reported | 06/30/2026 | 1150661446 |
| Principal investigator 1 | ModernaTX, Inc. | $7,840.80 | 02/29/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age | No dispute reported | 06/30/2026 | 1147153275 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,500.00 | 02/29/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older | No dispute reported | 06/30/2026 | 1128697604 |
| Principal investigator 1 | ModernaTX, Inc. | $1,947.51 | 02/28/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1147153271 |
| Principal investigator 1 | ModernaTX, Inc. | $3,754.89 | 02/26/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147153273 |
| Principal investigator 1 | Novavax Inc | $400.00 | 02/22/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 | No dispute reported | 06/30/2026 | 1123374445 |
| Principal investigator 1 | Novavax Inc | $267.30 | 02/22/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 | No dispute reported | 06/30/2026 | 1123376059 |
| Principal investigator 1 | Novavax Inc | $1,000.00 | 02/22/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 | No dispute reported | 06/30/2026 | 1123376607 |
| Principal investigator 1 | Novavax Inc | $2,792.00 | 02/22/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 | No dispute reported | 06/30/2026 | 1123377713 |
| Principal investigator 1 | Novavax Inc | $1,050.00 | 02/22/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 | No dispute reported | 06/30/2026 | 1123377715 |
| Principal investigator 1 | ModernaTX, Inc. | $2,680.00 | 02/21/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147183785 |
| Principal investigator 1 | PFIZER INC. | $1,850.00 | 02/14/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131095047 |
| Principal investigator 1 | BioNTech SE | $1,500.00 | 02/13/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | BNT162-21 | No dispute reported | 06/30/2026 | 1150661450 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $18,193.00 | 02/09/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128697592 |
| Principal investigator 1 | Mylan Technologies Inc. | $20,000.00 | 02/06/2024 | Non-covered Recipient Entity Research Centers of America, LLC | MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | No dispute reported | 06/30/2026 | 1134076011 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,322.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147665 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147667 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,488.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147669 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,976.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147671 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,013.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147673 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147675 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,001.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147679 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147691 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147693 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,013.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147695 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,976.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147697 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147699 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147701 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,488.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147703 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147705 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,322.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147707 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147709 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,013.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147711 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,976.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147713 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147715 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147717 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147719 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147721 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,488.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147723 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147725 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,322.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147727 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147729 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,013.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147731 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,976.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147733 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147735 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147737 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,488.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147739 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147741 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,322.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147743 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147745 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,013.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147747 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147749 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147751 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147753 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147755 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147757 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147759 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147761 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147763 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147765 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147767 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147769 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147771 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147773 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147775 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147777 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147779 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147781 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147783 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147785 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147787 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147789 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147791 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147793 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147795 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147797 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147799 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147801 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147803 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147805 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147807 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147809 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147811 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,565.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147813 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,001.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147817 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,001.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147819 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147851 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147853 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147855 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,322.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147857 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147859 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,488.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147861 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147863 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147865 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,013.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147867 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147869 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,322.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147871 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147873 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,488.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147875 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147877 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,013.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147879 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147881 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,322.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147883 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147885 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,488.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147887 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,013.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147889 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147891 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,322.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147893 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147895 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,488.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147897 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,013.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147899 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147901 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,322.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147903 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147905 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,488.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147907 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,013.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147909 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147911 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,322.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147913 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147915 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,488.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147917 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,013.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147919 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147921 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,322.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147923 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,127.00 | 02/02/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147925 |
| Principal investigator 1 | ModernaTX, Inc. | $885.30 | 02/02/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147183787 |
| Principal investigator 1 | ModernaTX, Inc. | $45,493.56 | 02/01/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1/2, randomized, observer-blind, parallel, dose-ranging study to evaluate the safety,reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines inhealthy adults 18 years of age | No dispute reported | 06/30/2026 | 1147153269 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170839 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170841 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170855 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170857 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170859 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170861 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170863 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170865 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170867 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170869 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170871 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170873 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170875 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170877 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170879 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170881 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170883 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170885 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170887 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170889 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170891 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170893 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170895 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170897 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170899 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170901 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170903 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170905 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Research Centers of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170907 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $480.00 | 01/30/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128697594 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $130.00 | 01/30/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128697600 |
| Principal investigator 1 | ModernaTX, Inc. | $7,392.33 | 01/29/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147153249 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $11,340.00 | 01/26/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128697590 |
| Principal investigator 1 | ModernaTX, Inc. | $3,917.42 | 01/25/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults | No dispute reported | 06/30/2026 | 1147153255 |
| Principal investigator 1 | Mylan Technologies Inc. | $59.79 | 01/24/2024 | Non-covered Recipient Entity Research Centers of America, LLC | MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | No dispute reported | 06/30/2026 | 1134076009 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $25,720.24 | 01/24/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1128697596 |
| Principal investigator 1 | PFIZER INC. | $4,500.00 | 01/23/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | No dispute reported | 06/30/2026 | 1131106605 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,000.00 | 01/22/2024 | Non-covered Recipient Entity Research Centers Of America,LLC | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1128697586 |
| Principal investigator 1 | ModernaTX, Inc. | $3,386.70 | 01/18/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1147153251 |
| Principal investigator 1 | ModernaTX, Inc. | $20,008.40 | 01/17/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147183755 |
| Principal investigator 1 | ModernaTX, Inc. | $2,160.00 | 01/17/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147183757 |
| Principal investigator 1 | ModernaTX, Inc. | $5,335.20 | 01/17/2024 | Non-covered Recipient Entity CENEXEL CLINICAL RESEARCH | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147183759 |
| Principal investigator 1 | ModernaTX, Inc. | $18,115.65 | 01/16/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147153253 |
| Principal investigator 1 | ModernaTX, Inc. | $375.00 | 01/16/2024 | Non-covered Recipient Entity CenExel RCA | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147182841 |
| Principal investigator 1 | H. Lundbeck A S | $12,400.00 | 01/11/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | STUDY WITH LU AF87908 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1145886096 |
| Principal investigator 1 | PFIZER INC. | $26,417.55 | 01/09/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131107072 |
| Principal investigator 1 | PFIZER INC. | $9,167.00 | 01/09/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131110024 |
| Principal investigator 1 | Mylan Technologies Inc. | $12,720.00 | 01/08/2024 | Non-covered Recipient Entity CenExel Clinical Research Inc | MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | No dispute reported | 06/30/2026 | 1134075935 |
| Principal investigator 1 | BioNTech SE | $1,340.00 | 01/05/2024 | Non-covered Recipient Entity RESEARCH CENTERS OF AMERICA LLC | BNT162-21 | No dispute reported | 06/30/2026 | 1150661452 |
| Principal investigator 1 | PFIZER INC. | $17,556.60 | 01/04/2024 | Non-covered Recipient Entity Research Centers of America LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH A NOVEL ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1131107178 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 01/03/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147681 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $165.00 | 01/03/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147683 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,094.00 | 01/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147687 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,001.00 | 01/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147689 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,001.00 | 01/03/2024 | Non-covered Recipient Entity Research Centers Of America | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121147815 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 01/03/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147821 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 01/03/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147823 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,293.00 | 01/03/2024 | Non-covered Recipient Entity Research Centers Of America | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121147825 |
| Principal investigator 1 | Mylan Technologies Inc. | $660.00 | 01/02/2024 | Non-covered Recipient Entity CenExel Clinical Research Inc | MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | No dispute reported | 06/30/2026 | 1134075937 |
| Principal investigator 1 | Mylan Technologies Inc. | $3,180.00 | 01/02/2024 | Non-covered Recipient Entity CenExel Clinical Research Inc | MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY | No dispute reported | 06/30/2026 | 1134075939 |